Evidence map›Paper›PMID 42802296›Full record

ArticleEuropean geriatric medicine2026

Diabetes medication use in the last year of life in people living with dementia in the United Kingdom and Australia.

Darshna Goordeen, Olivia K Hopkinson, Emily Reeve, Joshua D Niznik, Wallis C Y Lau, Li Wei, Jenni Ilomaki, J Simon Bell

Abstract read
PubMed Publisher
In one paragraph

Article in European geriatric medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Darshna GoordeenCentre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia. darshna.goordeen@monash.edu.ORCID http://orcid.org/0000-0002-6381-8745
Olivia K HopkinsonResearch Department of Practice and Policy, School of Pharmacy, University College London, London, UK.
Emily ReeveCentre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Joshua D NiznikEshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Wallis C Y LauResearch Department of Practice and Policy, School of Pharmacy, University College London, London, UK.
Li WeiResearch Department of Practice and Policy, School of Pharmacy, University College London, London, UK.
Jenni IlomakiCentre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
J Simon BellCentre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the prevalence of type 2 diabetes (T2D) medication use in the final 3,6, 9, and 12 months of life and explore patient factors associated with discontinuation in the 6 months prior to death in people living with dementia in the UK and Australia.

methodsLinked hospital and administrative data were used from the UK and Australia. We included individuals who died between July 2013 and June 2018. Logistic regressions estimated the association between age, sex, cardiovascular disease, chronic kidney disease (CKD), and cancer with discontinuation of T2D medications.

results10,088 UK and 6,436 Australian individuals were identified. From those supplied insulin in the last 12 months of life, there was a 25.6% reduction in use in the UK and 43.5% in Australia in the last 3 months of life, but minimal reduction in other medication classes. CKD was associated with metformin discontinuation in the last 6 months of life in the UK (OR 1.05, 95% CI 1.03-1.07) and Australia (OR 1.60, 95% CI 1.15-2.12).

conclusionGuideline-concordant discontinuation of metformin in the last 6 months of life was observed in those with CKD. Decreased insulin supply in those living with dementia was observed. There were lower rates of discontinuation of other glucose-lowering medications in the UK and Australia.

Indexed as

AntihyperglycaemicsDementiaEnd-of-life careType 2 diabetes

Identifiers

PMID42802296

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.